Bioinformatic landscapes of TTK-mediated ceRNA networks: new horizons for targeted therapy in lung adenocarcinoma

Abstract Objective This study identifies TTK as a prognostic LUAD biomarker regulated by a ceRNA network, driving immune evasion and therapeutic resistance. Methods An integrated in silico approach was employed using OncoMX, KM Plotter, UALCAN, and GEPIA2 for expression and survival analysis. Protein expression and promoter methylation were examined via HPA and OncoDB. Immune infiltration was mapped using TIMER 2.0 and CellTracer. Finally, molecular docking evaluated the predicted docking score of clinical inhibitors and natural flavonoids against the TTK ATP-binding pocket. Results TTK showed marked overexpression across cancers, especially in lung cancer (log 2 FC = 4.10). Elevated TTK expression predicted poorer OS (HR = 1.62, P = 3.7e-15), notably in female smoker subgroups. Protein levels confirmed higher TTK in LUAD with strong mRNA–protein correlation ( R = 0.845). Promoter hypomethylation and hotspot mutations supported its deregulation. TTK expression correlated with reduced CD8⁺ ( R = − 0.208), CD4⁺ ( R = − 0.333), and haematopoietic stem cells ( R = − 0.658), but increased suppressive immune cells ( R = 0.65), indicating an immune-evasive microenvironment. Since BAY 1,217,389 and CFI-402,257 are established TTK inhibitors (docking score = − 9.128 and − 8.417 Kcal/mol, respectively), their docking scores compared with hesperidin (docking score = − 9.407 Kcal/mol) showed similar docking strength, suggesting potential as a natural TTK inhibitor and combination therapy candidate. Key regulatory molecules of TTK included TF E2F1, hsa-let-7b-5p (miRNA), and TMPO-AS1 (lncRNA), forming the ceRNA axis. qRT-PCR confirmed TMPO-AS1 and TTK upregulation and hsa-let-7b-5p downregulation in lung cancer cell lines. Conclusion TTK is associated with LUAD progression through a putative TMPO-AS1/hsa-let-7b-5p regulatory axis, promoting immune evasion and serving as a high-affinity target for hesperidin therapy.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Research and Clinical Oncology
Published
2026-10-09
DOI
https://doi.org/10.1007/s00432-026-06641-3
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bioinformatic landscapes of TTK-mediated ceRNA networks: new horizons for targeted therapy in lung adenocarcinoma

Rajeev Nema, Camille Saini, Prerna Vats, Bhavika Baweja et al.
Journal of Cancer Research and Clinical Oncology
Cancer-related molecular mechanisms research
article

Bioinformatic landscapes of TTK-mediated ceRNA networks: new horizons for targeted therapy in lung adenocarcinoma

Rajeev Nema, Camille Saini, Prerna Vats, Bhavika Baweja, Kritika Jangir, Niranjan Kumar, Prachi Patidar
article en

Abstract

Abstract Objective This study identifies TTK as a prognostic LUAD biomarker regulated by a ceRNA network, driving immune evasion and therapeutic resistance. Methods An integrated in silico approach was employed using OncoMX, KM Plotter, UALCAN, and GEPIA2 for expression and survival analysis. Protein expression and promoter methylation were examined via HPA and OncoDB. Immune infiltration was mapped using TIMER 2.0 and CellTracer. Finally, molecular docking evaluated the predicted docking score of clinical inhibitors and natural flavonoids against the TTK ATP-binding pocket. Results TTK showed marked overexpression across cancers, especially in lung cancer (log 2 FC = 4.10). Elevated TTK expression predicted poorer OS (HR = 1.62, P = 3.7e-15), notably in female smoker subgroups. Protein levels confirmed higher TTK in LUAD with strong mRNA–protein correlation ( R = 0.845). Promoter hypomethylation and hotspot mutations supported its deregulation. TTK expression correlated with reduced CD8⁺ ( R = − 0.208), CD4⁺ ( R = − 0.333), and haematopoietic stem cells ( R = − 0.658), but increased suppressive immune cells ( R = 0.65), indicating an immune-evasive microenvironment. Since BAY 1,217,389 and CFI-402,257 are established TTK inhibitors (docking score = − 9.128 and − 8.417 Kcal/mol, respectively), their docking scores compared with hesperidin (docking score = − 9.407 Kcal/mol) showed similar docking strength, suggesting potential as a natural TTK inhibitor and combination therapy candidate. Key regulatory molecules of TTK included TF E2F1, hsa-let-7b-5p (miRNA), and TMPO-AS1 (lncRNA), forming the ceRNA axis. qRT-PCR confirmed TMPO-AS1 and TTK upregulation and hsa-let-7b-5p downregulation in lung cancer cell lines. Conclusion TTK is associated with LUAD progression through a putative TMPO-AS1/hsa-let-7b-5p regulatory axis, promoting immune evasion and serving as a high-affinity target for hesperidin therapy.

Journal of Cancer Research and Clinical Oncology
Manipal University Jaipur
Openalex Percentile: Top 18%
Cancer-related molecular mechanisms research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.